Clinical Trials Logo

Filter by:
NCT ID: NCT01410734 Completed - Gallstones Clinical Trials

Fluorescence Imaging on the da Vinci Surgical System for Intra-operative Near Infrared Imaging of the Biliary Tree (up to 2-weeks Post-operatively)

Start date: July 2011
Phase: N/A
Study type: Interventional

The investigators hypothesize that the da Vinci Fluorescence Imaging Vision System provides real-time endoscopic near infrared fluorescence imaging of the biliary anatomy as defined as identifying biliary vessels; either cystic duct, common hepatic duct (CHD) or common bile duct (CBD). Irradiation given to the patient during a classic cholangiography can be reduced.

NCT ID: NCT01410552 Completed - Tachycardia Clinical Trials

Inappropriate Shock Reduction wIth PARAD+ Rhythm DiScrimination

ISIS-ICD
Start date: October 2011
Phase: N/A
Study type: Interventional

ISIS- ICD study has been designed to evaluate the impact of PARAD+ algorithm on inappropriate shocks, in a general population implanted for primary or secondary prevention with a dual or tri chamber device at one year follow-up

NCT ID: NCT01410539 Completed - Stent Thrombosis Clinical Trials

Mechanism Of Stent Thrombosis (MOST) Study

Most
Start date: January 2010
Phase: Phase 4
Study type: Interventional

This study is designed to assess the pathophysiology of ST by studying the main procedural and anatomical factors involved in the genesis of ST such as those related to stent and the vascular wall, as well as to the individual platelet residual reactivity.

NCT ID: NCT01410448 Completed - Clinical trials for Kidney Transplantation

Everolimus in de Novo Kidney Transplant Recipients

NEVERWOUND
Start date: November 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate whether delayed (i.e. 28 ± 4 days post-transplant) administration of everolimus after transplantation reduces the risk of wound healing complications in comparison with immediate administration in de novo renal transplant patients (proportion of patients without wound/surgical complications related to initial transplant surgery) between randomization and 3 months after transplantation

NCT ID: NCT01410227 Completed - Clinical trials for Von Willebrand Disease

Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)

Start date: November 1, 2011
Phase: Phase 3
Study type: Interventional

The purpose of this Phase 3 study is to assess the pharmacokinetics of rVWF:rFVIII and rVWF, and to assess the safety and efficacy of rVWF:rFVIII and rVWF in the treatment of bleeding events in subjects with severe hereditary von Willebrand disease (VWD).

NCT ID: NCT01409343 Completed - Solid Tumors Clinical Trials

TrasGEX™: Phase 1 Study in Cancer Patients

Start date: July 2011
Phase: Phase 1
Study type: Interventional

This was a prospective, open label, multicenter study evaluating the safety, tolerability and pharmacokinetics of TrasGEX™ after intravenous administration in patients with HER-2 positive cancers. The effect of TrasGEX™ on the development of anti-drug antibodies and on tumour response was also evaluated.

NCT ID: NCT01408576 Completed - Clinical trials for Systemic Lupus Erythematosus

Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus

EMBODY4
Start date: July 2011
Phase: Phase 3
Study type: Interventional

The primary objective of the study is assess the safety and tolerability of long-term epratuzumab treatment in subjects with Systemic Lupus Erythematosus (SLE)

NCT ID: NCT01407159 Completed - Clinical trials for Type B Aortic Dissection

A Study in SurvIvors of Type B Aortic Dissection Undergoing Stenting

ASSIST
Start date: November 2011
Phase: N/A
Study type: Observational

Cohort study according to national regulatory guidelines: Non-interventional, observational cohort study. Pair-matched comparison with patients chosen from historical series. To evaluate the clinical and technical success as well as the safety and feasibility of the E-XL aortic stent used in complicated type B aortic dissection in addition to a classic stentgraft in a single procedure.

NCT ID: NCT01406938 Completed - Clinical trials for Moderate to Severe Plaque-type Psoriasis

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens

SCULPTURE
Start date: August 2011
Phase: Phase 3
Study type: Interventional

This study will assess the safety and efficacy of two different doses and two different dose regimens of subcutaneous secukinumab in patients that have moderate to severe, chronic, plaque-type psoriasis.

NCT ID: NCT01406093 Completed - Candidemia Clinical Trials

Early- and Late-onset Candidemia

Start date: May 2011
Phase: N/A
Study type: Observational

A timing diagnosis of candidemia is as important as the correct choice of empiric or targeted antifungal therapy. In the last years a growing body of knowledge has better characterized health-care associated (HCA) infections, which have been described in 2002 in outpatients with MRSA bloodstream infections. So far there is no compelling evidence that patients with HCA infections may develop candidemia before the usual timing of around 20-25 days after admission. Risk factors associated with HCA infections are represented by admission from long term chronic care facilities (LTCF), haemodialysis, previous admission or parenteral broad spectrum antibiotics. There are few data HCA features and early onset candidemias in the published literature. In this proposal, the investigators aim at studying early-onset candidemia in a retrospective study in one of the largest referral hospital in Italy with a consistent range of specialties ranging (bone marrow transplant, solid organ transplant, immunosuppressed patients, ICU, complex surgery). The investigators speculate that patients with candidemia diagnosed within 10 days (early-onset) by the admission have different risk factors and prognosis of those with a late diagnosis.